RU2063162C1 - Method for treating the cases of chronic prostatitis - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: method involves subcutaneously administering antibiotic into the area of external orifice of inguinal canal after preparatively administering lidase. EFFECT: enhanced effectiveness of treatment course.

Description

 The invention relates to medicine, namely to urology and can be used in the treatment of chronic prostatitis.

 Known methods of treating chronic prostatitis using antibacterial agents by oral, intramuscular and intravenous administration (Yunda I.F. 1974; Tiktinsky O.L. 1984).

 The prototype of the proposed method of administration is a method of treating chronic prostatitis, including the use of antibacterial agents by intramuscular injection (Pytel A. Ya. 1973).

 However, with this method of treatment, the choice of drug is limited by tropic conditions by selective accumulation of the drug in the tissues of the prostate gland. Optimum concentrations are achieved by increasing the dose, which causes general intoxication.

 The aim of the present invention is to increase therapeutic efficacy due to the selective accumulation of the drug in the prostate gland and the prevention of complications by reducing its dose, the antibiotic is administered subcutaneously in the projection area of the external opening of the inguinal canal after the preliminary administration of lidase.

 The method is as follows. In the inguinal region, on the projection of the external opening of the inguinal canal, lidase 32 units, dissolved in 5 ml of sterile physiological saline, is injected subcutaneously. After 5 to 7 minutes, an antibacterial drug, prepared in 5 ml of a 0.25% solution of novocaine, is introduced next. Separate administration of drugs is necessary because when administered in one syringe, lidase adsorbs the drug substance, reducing its therapeutic effect. As a test drug, an antibiotic gentamicin in an amount of 40 mg is used.

 The described injection site has a common lymphatic region with the prostate gland. The assumption that subcutaneous injection into the projection of the external opening of the inguinal canal can be used in the treatment of chronic prostatitis is purely theoretical and required clinical confirmation.

 The specified technique was applied in 20 patients with chronic prostatitis. As a control, 10 patients with this disease, to whom gentamicin was administered intramuscularly, served. In all patients, gentamicin was then determined in the secretion of the prostate gland. A statistically significant increase in the concentration of the drug was obtained 2.5-3 times compared with the concentration after intramuscular injection, as well as compared with the concentration of gentamicin in blood plasma according to S.M. Novashina, I.P. Fomina (1982) et al.

 Clinical examples: 1. Patient P. Okonchenko. 28 years old, suffers from chronic prostatitis and obstructive aspermia. For therapeutic purposes, 40 μg of gentamicin with preliminary administration of lidase was introduced lymphotropically according to the proposed method. The content of gentamicin in the secretion of the prostate gland 1 hour after administration was 3.21 mcg / l; in testicular biopsy after 4 hours 2.60 mcg / g, after 4 hours 2 mcg / g. The hospital stay was 15 days.

 2. Patient Bakhtyukov L.A. 27 years. Diagnosis: chronic prostatitis. For therapeutic purposes, according to the proposed method, gentamicin 40 μg was introduced. After an hour in the secretion of the prostate, its content is 3.07 μg / l, in the biopsy of the testis after 4 hours 1.90 μg / g, the content of the drug in the biopsy of the epididymis after 4 hours is 2.20 μg / g. The duration of treatment in the hospital was 16 days.

 3. Buntovsky S.A. 33 years old. Diagnosis: chronic prostatitis, oligochoospermia. After administration of the drug according to the same procedure, its content in the indicated media, respectively: 5.04 μg / l; 1.8 mcg / l; 0.25 mcg / l. Treatment for 14 days.

 4. Lebedevsky V.I. 31 years old (control). Diagnosis: chronic prostatitis. After administration with a therapeutic purpose, intramuscularly 40 μg of gentamicin, its content in the prostate secretion after 1 hour is 1.10 μg / l, and in the testicle biopsy after 4 hours 0.31 μg / g, the drug content in the biopsy of the epididymis after 4 hours is not determined. The treatment period was 26 days.

 5. Pasovets V.A. 24 years old (control). Diagnosis: chronic prostatitis. After intramuscular administration of gentamicin, its content was in the corresponding media: 0.90 μg / l; 0.34 μg / g; 0.28 mcg / g. The treatment period was 25 days.

 6. Kharchenko Yu. N., 35 years old (control). Diagnosis: chronic prostatitis. After intramuscular administration of gentamicin, its content, respectively: 0.7 μg / l; 0.00 mcg / g; 0.00 mcg / g. Duration of treatment is 27 days.

 Thus, high efficiency of the complex etiotropic and pathogenetic therapy is achieved due to the selective accumulation of the drug in the tissues of the prostate gland and the prevention of complications by reducing its dose.

 The proposed method allows the use of any antibacterial drugs available for subcutaneous administration.

 When calculating the optimal dose with the described method of administration, it is necessary to reduce the dose recommended for intramuscular administration (Novashin S.M. Fomina I.P. 1982) by 2 3 times.

 As a result, the treatment time is reduced, compared with the / m introduction, by an average of 10 12 days, which gives a significant economic effect.

 The method can be applied in wide medical practice in outpatient and inpatient urological patients.

Claims (1)

 A method of treating chronic prostatitis, including the use of antibacterial agents, characterized in that, in order to increase therapeutic efficacy due to the selective accumulation of the drug in the prostate gland and to prevent complications by reducing its dose, the antibiotic is injected subcutaneously into the projection area of the external opening of the inguinal canal after preliminary the introduction of lidase.